Key interindividual determinants in MDMA pharmacodynamics

References

• Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs. 1986;18(4):291–304.
   PubMed Web of Science ®Google Scholar
• Michael White C. How MDMA’s pharmacology and pharmacokinetics drive desired effects and harms. J Clin Pharmacol. 2014;54(3):245–252.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crim (UNDOC). UN Convention on Psychotropic Substances (1971). Available from: https://www.unodc.org/pdf/convention_1971_en.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2017: trends and developments Available from: http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf
   Google Scholar
• United Nations Office on Drugs and Crime (UNDOC). World drug report 2017. Available from: http://www.unodc.org/wdr2017/
   Google Scholar
• Global Drug Survey (GDS). 2016. Available from: https://www.globaldrugsurvey.com/wp-content/uploads/2016/06/TASTER-KEY-FINDINGS-FROM-GDS2016.pdf
   Google Scholar
• Bershad AK, Miller MA, Baggott MJ, et al. The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants? J Psychopharmacol. 2016;30(12):1248–1258.
   PubMed Web of Science ®Google Scholar
• Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68(12):1134–1140.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick MG, Baggott MJ, Mendelson JE, et al. MDMA effects consistent across laboratories. Psychopharmacology (Berl). 2014;231(19):3899–3905.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick M, Delton AW, Robertson TE, et al. Prosocial effects of MDMA: a measure of generosity. J Psychopharmacol. 2015;29(6):661–668.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick MG, de Wit H. MDMA: a social drug in a social context. Psychopharmacology (Berl). 2015;232(6):1155–1163.
   PubMed Web of Science ®Google Scholar
• Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci Biobehav Rev. 2015;57:433–446.
   PubMed Web of Science ®Google Scholar
• Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31(5):576–588.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9(11):1645–1652.
   PubMed Web of Science ®Google Scholar
• Mas M, Farré M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4 methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290(1):136–145.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther. 2011;90(2):246–255.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Saur MR, Gamma A, et al. Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23(4):396–404.
   PubMed Web of Science ®Google Scholar
• Cami J, Farré M, Mas M, et al. Human pharmacology of 3,4 methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20(4):455–466.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Farré M, Roset PN, et al. Pharmacology of MDMA in humans. Ann N Y Acad Sci. 2000;914:225–237.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Liechti ME. Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl). 2012;224(3):363–376.
   PubMed Web of Science ®Google Scholar
• Hysek C, Schmid Y, Rickli A, et al. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol. 2012 Aug;166(8):2277–2288.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Baumann C, Gamma A, et al. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22(5):513–521.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154(2):161–168.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Verkes RJ. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol. 2006;20(2):176–187.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther. 2009;86(2):160–166.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7(5):e36476.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Brugger R, Simmler LD, et al. Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther. 2012;340(2):286–294.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Fink AE, Simmler LD, et al. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol. 2013;33(5):658–666.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Simmler LD, Schillinger N, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol. 2014;17(3):371–381.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol. 2000;14(3):269–274.
   PubMed Web of Science ®Google Scholar
• Farré M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther. 2007;323(3):954–962.
   PubMed Web of Science ®Google Scholar
• Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2007;189(4):565–573.
   PubMed Web of Science ®Google Scholar
• Simmler LD, Hysek CM, Huwyler J, et al. Duloxetine prevents 3,4-methylenedioxymethamphetamine induced serotonin release in vitro and psychostimulant effects in humans. Eur Neuropsycho pharmacol. 2011;21(S3):S262-S263.
   Google Scholar
• Schmid Y, Rickli A, Schaffner A, et al. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther. 2015;353(1):102–111.
   PubMed Web of Science ®Google Scholar
• Seibert J, Hysek CM, Penno CA, et al. Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects. Neuroendocrinology. 2014;100:17–25.
   PubMed Web of Science ®Google Scholar
• Henry JA, Fallon JK, Kicman AT, et al. Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet. 1998;351(9118):1784.
   PubMed Web of Science ®Google Scholar
• Simmler LD, Hysek CM, Liechti ME. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab. 2011;96(9):2844–2850.
   PubMed Web of Science ®Google Scholar
• Forsling M, Fallon JK, Kicman AT, et al. Arginine vasopressin release in response to the administration of 3,4 methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor? J Pharm Pharmacol. 2001;53(10):1357–1363.
   PubMed Web of Science ®Google Scholar
• Kuypers KP, Dolder PC, Ramaekers JG, et al. Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies. J Psychopharmacol. 2017;31(5):589–598.
   PubMed Web of Science ®Google Scholar
• Bosker WM, Kuypers KP, Conen S, et al. Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss. Psychopharmacology (Berl). 2010;209(1):69–76.
   PubMed Web of Science ®Google Scholar
• Bosker WM, Kuypers KP, Conen S, et al. MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid. Psychopharmacology (Berl). 2012;222(3):367–376.
   PubMed Web of Science ®Google Scholar
• Peiró AM, Farré M, Roset PN, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology (Berl). 2013;225(4):883–893.
   PubMed Web of Science ®Google Scholar
• Farré M, Tomillero A, Pérez-Mañá C, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart. Eur Neuropsychopharmacol. 2015;25(10):1637–1649.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Vizeli P, Hysek CM, et al. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. Pharmacogenet Genomics. 2016;26(8):397–401.
   PubMed Web of Science ®Google Scholar
• Vizeli P, Schmid Y, Prestin K, et al. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharmacol. 2017;27(3):232–238.
   PubMed Web of Science ®Google Scholar
• European Drug Emergencies Network (Euro-DEN). Hospital emergency presentations and acute drug toxicity in Europe. Available from: http://www.emcdda.europa.eu/system/files/publications/2973/TD0216713ENN-1_Final%20pdf.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Recent changes in Europe’s MDMA/ecstasy market. Available from: http://www.emcdda.europa.eu/system/files/publications/2473/TD0116348ENN.pdf
   Google Scholar
• Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143–157.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Evaluation of sex-specific data in medical device clinical studies.2014. Available from: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM283707.pdf
   Google Scholar
• Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA (“Ecstasy”) after haloperidol pretreatment in healthy humans. EurNeuropsychopharmacol. 2000;10(4):289–295.
   PubMed Web of Science ®Google Scholar
• Samyn N, De Boeck G, Wood M, et al. Plasma, oral fluid and sweat wipe ecstasy concentrations incontrolled and real life conditions. Forensic Sci Int. 2002;128(1–2):90–97.
   PubMed Web of Science ®Google Scholar
• Kuypers KP, Samyn N, Ramaekers JG. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology (Berl). 2006;187(4):467–475.
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Kuypers KP. Acute effects of 3,4 methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol. Neuropsychopharmacology. 2006;31(5):1048–1055.
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Kuypers KP, Samyn N. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction. 2006;101(11):1614–1621.
   PubMed Web of Science ®Google Scholar
• Kuypers KP, Wingen M, Samyn N, et al. Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night. Psychopharmacology (Berl). 2007;192(1):111–119.
   PubMed Web of Science ®Google Scholar
• Kuypers KP, Wingen M, Ramaekers JG. Memory and mood during the night and in the morning after repeated evening doses of MDMA. J Psychopharmacol. 2008;22(8):895–903.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Wezenberg E, Valkenberg MM, et al. Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers. Psychopharmacology (Berl). 2008;197(3):465–474.
   PubMed Web of Science ®Google Scholar
• Kolbrich EA, Goodwin RS, Gorelick DA, et al. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol. 2008;28(4):432–440.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Schoemaker RC, Touw DJ, et al. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. J Psychopharmacol. 2010;24(2):155–164.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Kramers C, Sweep FC, et al. Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology. J Psychopharmacol. 2010;24(2):165–174.
   PubMed Web of Science ®Google Scholar
• van Wel JH, Kuypers KP, Theunissen EL, et al. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One. 2012;7(7):e40187.
   PubMed Web of Science ®Google Scholar
• Parrott AC, Gibbs A, Scholey AB, et al. MDMA and methamphetamine: some paradoxical negative and positive mood changes in acute dose laboratory study. Psychopharmacology (Berl). 2011;215(3):527–536.
   PubMed Web of Science ®Google Scholar
• Stough C, Downey LA, King R, et al. The acute effects of 3,4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study. Accid Anal Prev. 2012;45:493–497.
   PubMed Web of Science ®Google Scholar
• Veldstra JL, Brookhuis KA, de Waard D, et al. Effects of alcohol (BAC 0.5‰) and ecstasy (MDMA 100 mg) on simulated driving performance and traffic safety. Psychopharmacology (Berl). 2012;222(3):377–390.
   PubMed Web of Science ®Google Scholar
• Kuypers KP, de la Torre R, Farre M, et al. Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. Br J Pharmacol. 2013;168(3):607–617.
   PubMed Web of Science ®Google Scholar
• Kuypers KP, de la Torre R, Farre M, et al. No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One. 2014;9(6):e100719.
   PubMed Web of Science ®Google Scholar
• de Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, et al. Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology. 2014;87:198–205.
   PubMed Web of Science ®Google Scholar
• Hartman RL, Desrosiers NA, Barnes AJ, et al. 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. Anal Bioanal Chem. 2014;406(2):587–599.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Hysek CM, Simmler LD, et al. Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol. 2014;28(9):847–856.
   PubMed Web of Science ®Google Scholar
• van Heugten-Van der Kloet D, Giesbrecht T, van Wel J, et al. MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Res. 2015;228(3):907–912.
   PubMed Web of Science ®Google Scholar
• Pardo-Lozano R, Farré M, Yubero-Lahoz S, et al. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). PLoS One. 2012;7(10):e47599.
   PubMed Web of Science ®Google Scholar
• Yubero-Lahoz S, Pardo R, Farré M, et al. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet. 2011 May;50(5):319–329.
   PubMed Web of Science ®Google Scholar
• Kolbrich EA, Goodwin RS, Gorelick DA, et al. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit. 2008;30(3):320–332.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Müller F, Schmid Y, et al. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (Berl). 2017 May 27. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Rosenson J, Smollin C, Sporer KA, et al. Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med. 2007;49(2):164–71, 171.e1.
   PubMed Web of Science ®Google Scholar
• Yubero-Lahoz S, Pardo R, Farre M, et al. Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metab Pharmacokinet. 2012;27(6):605–613.
   PubMed Web of Science ®Google Scholar
• Becker JB, McClellan ML, Reed BG. Sex differences, gender and addiction. J Neurosci Res. 2017;95(1–2):136–147.
   PubMed Web of Science ®Google Scholar
• Moran-Santa Maria MM, Flanagan J, Brady K. Ovarian hormones and drug abuse. Curr Psychiatry Rep. 2014;16(11):511.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Collection of Race and Ethnicity Data in Clinical Trials. 2016. Available from: https://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126396.pdf
   Google Scholar
• European Medicines Agency (EMA). ICH topic E 5 (R1) ethnic factors in the acceptability of foreign clinical data. 1998. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf
   Google Scholar
• Goh LL, Lim CW, Sim WC, et al. Analysis of genetic variation in CYP450 genes for clinical implementation. PLoS One. 2017;12(1):e0169233.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Farré M, Mathúna BO, et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol. 2005;61(7):551–554.
   PubMed Web of Science ®Google Scholar
• Kreth K, Kovar K, Schwab M, et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs. Biochem Pharmacol. 2000;59(12):1563–1571.
   PubMed Web of Science ®Google Scholar
• Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol (Phila). 2015;53(6):501–510.
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN, Kearns GL, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998;8(5):403–410.
   PubMedGoogle Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol. 2001;57(10):717–722.
   PubMed Web of Science ®Google Scholar
• Labbé L, Sirois C, Pilote S, et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics. 2000;10(5):425–438.
   PubMedGoogle Scholar
• Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51(2):169–173.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, et al. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet. 2012;3:235.
   PubMedGoogle Scholar
• Aitchison KJ, Tsapakis EM, Huezo-Diaz P, et al. Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. J Psychopharmacol. 2012;26(3):408–418.
   PubMed Web of Science ®Google Scholar
• Wolff K, Tsapakis EM, Pariante CM, et al. Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J Psychopharmacol. 2012;26(3):419–428.
   PubMed Web of Science ®Google Scholar
• Yubero-Lahoz S, Kuypers KP, Ramaekers JG, et al. Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake. Psychopharmacology (Berl). 2015;232(11):1921–1929.
   PubMed Web of Science ®Google Scholar
• Chen FS, Kumsta R, Dvorak F, et al. Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach. Transl Psychiatry. 2015;5:e664.
   PubMed Web of Science ®Google Scholar
• Bershad AK, Weafer JJ, Kirkpatrick MG, et al. Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc Neurosci. 2016;11(6):592–599.
   PubMed Web of Science ®Google Scholar
• O’Mathúna B, Farré M, Rostami-Hodjegan A, et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol. 2008;28(5):523–529.
   PubMed Web of Science ®Google Scholar
• Farré M, de la Torre R, Mathúna BO, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl). 2004;173(3–4):364–375.
   PubMed Web of Science ®Google Scholar
• Papaseit E, Vázquez A, Pérez-Mañá C, et al. Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). Intensive Care Med. 2012;38(7):1239–1240.
   PubMed Web of Science ®Google Scholar
• Armenian P, Mamantov TM, Tsutaoka BT, et al. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series. J Intensive Care Med. 2013;28(4):252–258.
   PubMedGoogle Scholar
• Hoggett K, McCoubrie D, Fatovich DM. Ecstasy-induced acute coronary syndrome: something to rave about. Emerg Med Australas. 2012;24(3):339–342.
   PubMed Web of Science ®Google Scholar
• Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96(6):678–685.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to Ecstasy use. Case-series of emergency department visits. Swiss Med Wkly. 2005;135(43–44):652–657.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Farré M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26(2):137–144.
   PubMed Web of Science ®Google Scholar
• Schifano F, Corkery J, Naidoo V, et al. Overview of amphetamine-type stimulant mortality data–UK, 1997–2007. Neuropsychobiology. 2010;61(3):122–130.
   PubMed Web of Science ®Google Scholar
• Milroy CM. “Ecstasy” associated deaths: what is a fatal concentration? Analysis of a case series. Forensic Sci Med Pathol. 2011;7(3):248–252.
   PubMed Web of Science ®Google Scholar
• Colak Y, Tuncer I, Enc FY, et al. Ecstasy induced fatal hepatic failure. J Gastrointestin Liver Dis. 2011;20(2):215–216.
   PubMed Web of Science ®Google Scholar
• Vanden Eede H, Montenij LJ, Touw DJ, et al. Rhabdomyolysis in MDMA intoxication: a rapid and underestimated killer. “Clean” Ecstasy, a safe party drug? J Emerg Med. 2012;42(6):655–658.
   PubMed Web of Science ®Google Scholar
• Ghatol A, Kazory A. Ecstasy-associated acute severe hyponatremia and cerebral edema: a role for osmotic diuresis? J Emerg Med. 2012;42(6):e137–40.
   PubMedGoogle Scholar
• Fernando T, Gilbert JD, Carroll CM, et al. Ecstasy and suicide. J Forensic Sci. 2012;57(4):1137–1139.
   PubMed Web of Science ®Google Scholar
• Nadkarni GN, Hoskote SS, Piotrkowski J, et al. Serotonin syndrome, disseminated intravascular coagulation, and hepatitis after a single ingestion of MDMA in an Asian woman. Am J Ther. 2014;21(4):e117–9.
   PubMed Web of Science ®Google Scholar
• Vakde T, Diaz M, Uday K, et al. Rapidly reversible multiorgan failure after ingestion of “Molly” (pure 3,4-methylenedioxymethamphetamine): a case report. J Med Case Rep. 2014;8:204.
   PubMedGoogle Scholar
• Davies O, Batajoo-Shrestha B, Sosa-Popoteur J, et al. Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA. Heart Lung. 2014;43(2):117–119.
   PubMed Web of Science ®Google Scholar
• Shelton CP, Rosini JM. Multisystem organ failure and death resulting from ingestion of “Molly” (3,4-methylenedioxymethamphetamine). J Emerg Nurs. 2015;41(5):447–450.
   PubMed Web of Science ®Google Scholar
• Maharaj R, Pingitore A, Menon K, et al. Images of the month: MDMA-induced acute liver failure and transient abdominal pneumatosis. Am J Gastroenterol. 2015;110(7):963.
   PubMed Web of Science ®Google Scholar
• Atayan Y, Çağın YF, Erdoğan MA, et al. Ecstasy induced acute hepatic failure. Case reports. Acta Gastroenterol Belg. 2015;78(1):53–55.
   PubMed Web of Science ®Google Scholar
• Chandra YG, Shetty AR, Jayanth SH, et al. A death due to ecstasy - a case report. Med Leg J. 2016;84(1):46–48.
   PubMedGoogle Scholar
• Baggott MJ, Garrison KJ, Coyle JR, et al. MDMA impairs response to water intake in healthy volunteers. Adv Pharmacol Sci. 2016;2016:2175896.
   PubMedGoogle Scholar
• Rogers G, Elston J, Garside R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009;13(6):iii–iv, ix–xii, 1–315.
   PubMed Web of Science ®Google Scholar
• Budisavljevic MN, Stewart L, Sahn SA, et al. Hyponatremia associated with 3,4-methylenedioxymethylamphetamine (“Ecstasy”) abuse. Am J Med Sci. 2003;326(2):89–93.
   PubMed Web of Science ®Google Scholar
• van Dijken GD, Blom RE, Hené RJ, et al. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant. 2013;28(9):2277–2283.
   PubMed Web of Science ®Google Scholar
• Moritz ML, Kalantar-Zadeh K, Ayus JC. Ecstacy-associated hyponatremia: why are women at risk? Nephrol Dial Transplant. 2013;28(9):2206–2209.
   PubMed Web of Science ®Google Scholar
• Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with “ecstasy” and “eve” misuse. J Clin Pathol. 1996;49(2):149–153.
   PubMed Web of Science ®Google Scholar
• Harrington RD, Woodward JA, Hooton TM, et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 1999;159(18):2221–2224.
   PubMed Web of Science ®Google Scholar
• Mohamed WM, Ben Hamida S, Cassel JC, et al. MDMA: interactions with other psychoactive drugs. Pharmacol Biochem Behav. 2011;99(4):759–774.
   PubMed Web of Science ®Google Scholar
• Pilgrim JL, Gerostamoulos D, Woodford N, et al. Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int. 2012;215(1–3):184–188.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Domes G, Liechti ME. MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharmacology (Berl). 2012;222(2):293–302.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Sweep FC, van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4(4):359–366.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Wall MB, Erritzoe D, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2014;17(4):527–540.
   PubMed Web of Science ®Google Scholar
• Danforth AL, Struble CM, Yazar-Klosinski B, et al. MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:237–249.
   PubMed Web of Science ®Google Scholar
• Huestis MA, Tyndale RF. Designer drugs 2.0. Clin Pharmacol Ther. 2017;101(2):152–157.
   PubMed Web of Science ®Google Scholar
• Yazar-Klosinski BB, Mithoefer MC. Potential psychiatric uses for MDMA. Clin Pharmacol Ther. 2017;101(2):194–196.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3:481–488.
   PubMed Web of Science ®Google Scholar
• Bouso JC, Doblin R, Farré M, et al. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008;40(3):225–236.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439–452.
   PubMed Web of Science ®Google Scholar
• Oehen P, Traber R, Widmer V, et al. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27(1):40–52.
   PubMed Web of Science ®Google Scholar
• Green AR, King MV, Shortall SE, Fone KC. Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br J Pharmacol. 2012;166(5):1523–1536.
   PubMed Web of Science ®Google Scholar
• Baumann MH, Rothman RB. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol. 2009;88:257–296.
   PubMed Web of Science ®Google Scholar
• Baumann MH, Zolkowska D, Kim I, et al. Effects of dose and route of administration on pharmacokinetics of (+ or -) −3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos. 2009;37(11):2163–2170.
   PubMed Web of Science ®Google Scholar
• Concheiro M, Baumann MH, Scheidweiler KB, et al. Nonlinear pharmacokinetics of (±)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos. 2014;42(1):119–125.
   PubMed Web of Science ®Google Scholar
• Mueller M, Goodwin AK, Ator NA, et al. Metabolism and disposition of 3,4-methylenedioxymethamphetamine (“ecstasy”) in baboons after oral administration: comparison with humans reveals marked differences. J Pharmacol Exp Ther. 2011;338(1):310–317.
   PubMed Web of Science ®Google Scholar
• Goodwin AK, Mueller M, Shell CD, et al. Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons. J Pharmacol Exp Ther. 2013;345(3):342–353.
   PubMed Web of Science ®Google Scholar
• Fonsart J, Menet MC, Declèves X, et al. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Toxicol Appl Pharmacol. 2008;230(1):117–125.
   PubMed Web of Science ®Google Scholar
• Chu T, Kumagai Y, DiStefano EW, et al. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol. 1996;51(6):789–796.
   PubMed Web of Science ®Google Scholar
• Roberts CA, Quednow BB, Montgomery C, et al. MDMA and brain activity during neurocognitive performance: an overview of neuroimaging studies with abstinent ‘Ecstasy’ users. Neurosci Biobehav Rev. 2018;84:470-482.
   Web of Science ®Google Scholar
• Mueller F, Lenz C, Steiner M, et al. Neuroimaging in moderate MDMA use: a systematic review. Neurosci Biobehav Rev. 2016;62:21–34.
   PubMed Web of Science ®Google Scholar